Overview
Herpes labialis, commonly known as cold sores or fever blisters, is a recurrent viral infection caused by the herpes simplex virus type 1 (HSV-1). This condition primarily affects the oral mucosa, manifesting as painful vesicles that typically erupt around the lips. Given its high prevalence and recurrent nature, herpes labialis significantly impacts quality of life, causing discomfort, psychological distress, and potential social embarrassment. Effective management is crucial in day-to-day practice to alleviate symptoms and reduce recurrence rates 13.Pathophysiology
Herpes labialis arises from the reactivation of latent HSV-1 within trigeminal ganglia. After initial infection, the virus establishes latency, periodically reactivating due to various triggers such as stress, immunosuppression, or environmental factors. Reactivation leads to viral shedding and subsequent replication in epithelial cells of the lip and surrounding areas, resulting in characteristic vesicular lesions. The immune response, including both innate and adaptive mechanisms, plays a critical role in controlling viral spread but often fails to prevent lesion formation completely. Recent studies suggest that photobiomodulation therapy (PBMT) and low-level laser therapy (LLLT) may modulate this immune response, potentially reducing pain and accelerating healing processes 12.Epidemiology
Herpes labialis is highly prevalent globally, affecting a significant portion of the population. Estimates suggest that up to 60% of adults have antibodies to HSV-1, indicating prior infection 3. The condition predominantly affects individuals aged 10 to 30 but can occur at any age. There is no significant sex predilection, though some studies suggest a slightly higher incidence in females. Geographic distribution varies, with no clear regional predominance, though socioeconomic factors and hygiene practices may influence exposure rates. Trends over time show stable prevalence, though improved diagnostic techniques might lead to higher reported incidences 3.Clinical Presentation
The typical presentation of herpes labialis includes prodromal symptoms such as tingling, itching, or burning sensations around the lips, followed by the appearance of small, painful vesicles that coalesce into larger ulcers. These lesions are often preceded by systemic symptoms like fever or malaise in primary infections. Atypical presentations can include intraoral lesions or more generalized rashes, though these are less common. Red-flag features include lesions that do not heal within two weeks, significant systemic symptoms, or signs of secondary infection, which warrant further evaluation 3.Diagnosis
Diagnosis of herpes labialis is primarily clinical, based on characteristic symptoms and lesion morphology. Laboratory confirmation is rarely necessary but can be achieved through viral culture, PCR testing, or serology in atypical cases. Specific criteria for diagnosis include:
Clinical Criteria:
- Presence of grouped vesicles or ulcers around the lips
- Prodromal symptoms (tingling, itching) preceding lesion formation
- History of recurrent episodes
Tests:
- Viral Culture: Not routinely required but useful for atypical presentations
- PCR Testing: Highly sensitive for confirming HSV-1 presence in lesions
Differential Diagnosis:
- Allergic Reactions: Often presents without prodromal symptoms and lacks recurrent nature
- Contact Dermatitis: Lesions are typically localized to areas of contact and lack vesicles
- Oral Candidiasis: Characterized by white patches that can be scraped off, often in immunocompromised individuals 3Management
First-Line Treatment
Topical Antivirals:
Acyclovir Cream: Apply 5 times daily for 5 days
Penciclovir Cream: Apply every 2 hours while awake for 4 days
Famciclovir: Oral dosing of 125 mg twice daily for 1 day (for episodic treatment)
Valacyclovir: Oral dosing of 2 g once daily for 1 day (for episodic treatment)
Contraindications: Avoid in patients with known hypersensitivity to the drug 3Second-Line Treatment
Systemic Antivirals:
Famciclovir: 250 mg three times daily for 7-10 days (for severe or frequent recurrences)
Valacyclovir: 500 mg twice daily for 7-10 days (for severe or frequent recurrences)
Monitoring: Regular assessment for side effects such as nausea, headache, and elevated liver enzymes 3Refractory Cases / Specialist Referral
Photobiomodulation Therapy (PBMT): 650 nm laser, 100 mW, 4.7 J/cm2 applied at multiple sessions (e.g., 24, 48, 72 hours post-onset)
Low-Level Laser Therapy (LLLT): Wavelengths between 632.5-870 nm, power output 5-80 mW, energy density 2.04-48 J/cm2
High-Intensity Laser Therapy (HILT) + Photodynamic Therapy (PDT): Combination therapies may be considered under specialist guidance
Referral Indicators: Persistent or severe symptoms unresponsive to standard treatments, recurrent infections despite prophylactic measures 124Complications
Acute Complications
Secondary Bacterial Infections: May occur if lesions are scratched or become necrotic, requiring topical or systemic antibiotics
Ophthalmic Involvement: Rare but serious if lesions extend near the eye, potentially leading to keratitisLong-Term Complications
Chronic Recurrence: Frequent outbreaks can lead to psychological distress and impact quality of life
Prophylaxis Failure: Some patients may not respond adequately to prophylactic treatments, necessitating alternative strategies or specialist referral 3Prognosis & Follow-Up
The prognosis for herpes labialis is generally good with appropriate management, though recurrence is common. Prognostic indicators include the frequency of recurrences, severity of symptoms, and response to treatment. Recommended follow-up intervals include:
Initial Episode: Follow-up within 1-2 weeks to ensure healing and address any complications
Recurrent Episodes: Regular monitoring every 3-6 months, especially in patients with frequent recurrences
Monitoring: Assess symptom control, recurrence patterns, and adherence to prophylactic regimens 3Special Populations
Pregnancy
Management: Topical acyclovir is generally considered safe; systemic antivirals should be used cautiously and only if necessary, with close monitoring
Considerations: Avoid systemic treatments unless absolutely required due to potential fetal risks 3Pediatrics
Treatment: Topical antivirals are preferred; systemic treatments are reserved for severe cases under pediatric supervision
Monitoring: Frequent follow-ups to ensure safety and efficacy, given the developing immune system 3Elderly
Management: Focus on minimizing systemic side effects; topical treatments are often preferred
Considerations: Increased risk of complications; close monitoring for drug interactions and immune status 3Key Recommendations
Initiate treatment with topical acyclovir or penciclovir within 24 hours of symptom onset for optimal efficacy (Evidence: Strong 3)
Consider oral famciclovir or valacyclovir for severe or frequent recurrences (Evidence: Moderate 3)
Use photobiomodulation therapy as an alternative or adjunctive treatment for pain relief and accelerated healing (Evidence: Moderate 1)
Monitor for secondary bacterial infections, especially in lesions that are scratched or show signs of necrosis (Evidence: Expert opinion)
Refer patients with refractory cases or persistent symptoms to specialists for advanced therapies such as HILT or PDT (Evidence: Expert opinion)
Regular follow-up every 3-6 months for patients with frequent recurrences to adjust prophylactic strategies (Evidence: Moderate 3)
In pregnant women, prioritize topical treatments and use systemic antivirals cautiously with close monitoring (Evidence: Moderate 3)
For pediatric patients, opt for topical antivirals and ensure close pediatric supervision (Evidence: Moderate 3)
In elderly patients, focus on minimizing systemic side effects and monitor for drug interactions (Evidence: Moderate 3)
Evaluate psychological impact and provide support for patients experiencing significant distress due to recurrent episodes (Evidence: Expert opinion)References
1 Gaizeh Al-Hallak MA, Chalhoub K, Hsaian JA, Aljoujou AA. Efficacy of photobiomodulation therapy in recurrent herpes labialis management: a randomized controlled trial. Clinical oral investigations 2024. link
2 Al-Maweri SA, Kalakonda B, AlAizari NA, Al-Soneidar WA, Ashraf S, Abdulrab S et al.. Efficacy of low-level laser therapy in management of recurrent herpes labialis: a systematic review. Lasers in medical science 2018. link
3 Harmenberg J, Oberg B, Spruance S. Prevention of ulcerative lesions by episodic treatment of recurrent herpes labialis: A literature review. Acta dermato-venereologica 2010. link
4 Marotti J, Sperandio FF, Fregnani ER, Aranha AC, de Freitas PM, Eduardo Cde P. High-intensity laser and photodynamic therapy as a treatment for recurrent herpes labialis. Photomedicine and laser surgery 2010. link